T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
Overall, our findings highlight the potential of CC-3 for clinical evaluation as a therapeutic option for patients with endometrial cancer.
Authors
- Helmut R. Salih (ORCID: https://orcid.org/0000-0002-6719-1847)
- Ilona Hagelstein
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Suzanne Greiner (ORCID: https://orcid.org/0000-0002-1378-2975)
- Martina S. Lutz (ORCID: https://orcid.org/0000-0003-2576-2442)
- G. Jung
- Latifa Zekri (ORCID: https://orcid.org/0000-0002-9844-7948)
- Melanie Märklin (ORCID: https://orcid.org/0000-0002-2920-3894)
- J. Mauermann
Institutions
- STZ eyetrial (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1186/s12967-025-06825-4
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06
Funders
- Carl-Zeiss-Stiftung
- Deutsche Forschungsgemeinschaft
- Eberhard Karls Universität Tübingen
- Bundesministerium für Bildung und Forschung
- Deutsche Krebshilfe
- Universitätsklinikum Tübingen